13G Filing: Balyasny Asset Management and Sunesis Pharmaceuticals Inc (SNSS)

Page 17 of 30

Page 17 of 30 – SEC Filing


(8) Atlas Enhanced Fund, L.P. is a Delaware limited partnership (AEF LP), with its principal
business office at 181 West Madison, Suite 3600, Chicago, IL 60602. AEF LP owns 30.90% of the equity interests in AEMF.

(9) Atlas Enhanced Fund, Ltd. is a Cayman corporation (AEF LTD), with its principal business
office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AEF LTD owns 69.09% of the equity interests in AEMF.

(10) Atlas Fundamental Trading Master Fund Ltd. is a Cayman corporation (AFT MASTER), with
its principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies.

(11) Atlas Fundamental Trading Fund, L.P., is a Delaware limited partnership (AFT LP), with
its principal business office at 181 West Madison, Suite 3600, Chicago, IL 60602. AFT LP owns 37.03% of the equity interests in AFT MASTER.

(12) Atlas Fundamental Trading Fund Ltd. is a Cayman corporation (AFT LTD), with its
principal business office at c/o Maples Corporate Services Limited, P.O. Box 309, Ugland House, George Town, Grand Cayman KY1-1104, Cayman Islands, British West Indies. AFT LTD owns 62.85% of the equity interests in AFT MASTER

(13) Balyasny Asset Management L.P. is a Delaware limited partnership (BAM), with its
principal business office at 181 West Madison, Suite 3600, and Chicago, IL 60602. BAM is the investment manager to each of AMF, AG, AGI, AIF LLC, AIF LTD, AGJ, AEMF, AEF LP, AEF LTD, AFT MASTER, AFT LP and AFT LTD.

(14)Dmitry Balyasny, a United States citizen whose business address is 181 West Madison, Suite 3600,
Chicago, IL 60602. Dmitry Balyasny is the sole managing member of the general partner of BAM.

(d) Title of Class of Securities:
Common Stock
(e) CUSIP Number: 867328700

Page 17 of 30 Pages

Follow Viracta Therapeutics Inc. (NASDAQ:VIRX)

Page 17 of 30